CD38 and Miyoshi myopathy: Selinexor is approved for use with low‐dose dexamethasone in heavily pretreated MM or with bortezomib and dexamethasone (XVd) in patients with ≥1 prior therapy [5, 6]; other combinations with IMiDs, PIs and anti‐CD38 mAbs are also listed in national guidelines [10].